Jessica Mendoza

Well, I see Novo Nordisk putting up the biggest gains.

Well, I see Novo Nordisk putting up the biggest gains.

Ozempic launched in the U.S. in 2018, just about a year after Jorgensen took over as CEO. The drug is approved for treating diabetes, but people quickly realized that the weekly doses didn't just help control blood sugar. They could help control weight. And that's when Ozempic really took off.

Ozempic launched in the U.S. in 2018, just about a year after Jorgensen took over as CEO. The drug is approved for treating diabetes, but people quickly realized that the weekly doses didn't just help control blood sugar. They could help control weight. And that's when Ozempic really took off.

Ozempic launched in the U.S. in 2018, just about a year after Jorgensen took over as CEO. The drug is approved for treating diabetes, but people quickly realized that the weekly doses didn't just help control blood sugar. They could help control weight. And that's when Ozempic really took off.

Ozempic and Wegovy are what's known as GLP-1s, now one of the most successful drug categories in the industry. Novo's biggest challenger in the space is an American company, one that it's competed with for something like a century, Eli Lilly.

Ozempic and Wegovy are what's known as GLP-1s, now one of the most successful drug categories in the industry. Novo's biggest challenger in the space is an American company, one that it's competed with for something like a century, Eli Lilly.

Ozempic and Wegovy are what's known as GLP-1s, now one of the most successful drug categories in the industry. Novo's biggest challenger in the space is an American company, one that it's competed with for something like a century, Eli Lilly.

What did that look like post-ozempic?

What did that look like post-ozempic?

What did that look like post-ozempic?

The result would be a blockbuster for Eli Lilly. When the Indiana company presented early data of its new drug at a medical meeting, one specialist made a bold prediction.

The result would be a blockbuster for Eli Lilly. When the Indiana company presented early data of its new drug at a medical meeting, one specialist made a bold prediction.

The result would be a blockbuster for Eli Lilly. When the Indiana company presented early data of its new drug at a medical meeting, one specialist made a bold prediction.

Okay. In 2022, Lilly released its answer to Ozempic, Monjaro, approved for type 2 diabetes. The following year, the company came out with its answer to Wigovi. Lilly called its weight loss drug Zepbound.

Okay. In 2022, Lilly released its answer to Ozempic, Monjaro, approved for type 2 diabetes. The following year, the company came out with its answer to Wigovi. Lilly called its weight loss drug Zepbound.

Okay. In 2022, Lilly released its answer to Ozempic, Monjaro, approved for type 2 diabetes. The following year, the company came out with its answer to Wigovi. Lilly called its weight loss drug Zepbound.

Soon, Novo CEO Lars Juergensen saw his company's lead slipping. Not only was Novo's old rival eating up market share, Novo also found itself struggling to keep up with demand. The company just didn't have manufacturing capacity to produce Ozempic and Wegovy fast enough, and shortages became common, which also opened the way for knockoff versions of the drugs to further erode Novo's market share.

Soon, Novo CEO Lars Juergensen saw his company's lead slipping. Not only was Novo's old rival eating up market share, Novo also found itself struggling to keep up with demand. The company just didn't have manufacturing capacity to produce Ozempic and Wegovy fast enough, and shortages became common, which also opened the way for knockoff versions of the drugs to further erode Novo's market share.

Soon, Novo CEO Lars Juergensen saw his company's lead slipping. Not only was Novo's old rival eating up market share, Novo also found itself struggling to keep up with demand. The company just didn't have manufacturing capacity to produce Ozempic and Wegovy fast enough, and shortages became common, which also opened the way for knockoff versions of the drugs to further erode Novo's market share.